Drugs

, Volume 28, Issue 4, pp 292–323 | Cite as

Piroxicam

A Reappraisal of its Pharmacology and Therapeutic Efficacy
  • R. N. Brogden
  • R. C. Heel
  • T. M. Speight
  • G. S. Avery
Drug Evaluations

Summary

Synopsis: Piroxicam1 is a chemically different non-steroidal anti-inflammatory drug with a long half-life which enables it to be administered once daily. This member of the oxicam series of compounds is now well established in the treatment of rheumatoid arthritis and osteoarthritis and has been shown to be a suitable alternative to aspirin, indomethacin, naproxen, ibuprofen, ketoprofen, sulindac, phenylbutazone and diclofenac in the treatment of rheumatic diseases. Open trials in many thousands of patients in hospital clinics and in general practice have demonstrated its analgesic and anti-inflammatory efficacy in a wide cross-section of patients with rheumatic diseases, when administered once daily either at night or in the morning, and recent studies have demonstrated its usefulness in musculoskeletal disorders, dysmenorrhoea and postoperative pain. Such studies have also demonstrated the generally good tolerability of piroxicam 20mg daily. As with other non-steroidal anti-inflammatory drugs, gastrointestinal complaints are the most frequently reported side effects. The frequency and severity of these effects are dose related. Thus, piroxicam is now well established in the treatment of rheumatic diseases and offers an alternative to other analgesics in various pain states.

Pharmacodynamic Properties: In nonspecific animal models of inflammation, piroxicam is similar in potency to indomethacin. As an analgesic, piroxicam is more potent than aspirin, fenoprofen, ibuprofen, naproxen or phenylbutazone in inhibiting phenylquinone-induced writhing. The analgesic effect of piroxicam lasted for 7 hours in mice (phenylbenzquinone test) and for 48 hours in dogs (urate-induced knee pain). In animals, the ulcerogenic activity of piroxicam is less than that of indomethacin, phenylbutazone, diclofenac, ibuprofen and mefenamic acid, when ulcerogenic dosages are related to dosages that suppress experimental inflammation. In man, piroxicam 20mg daily caused less faecal blood loss than aspirin 3.9g daily, although comparisons with other non-steroidal anti-inflammatory agents have not been conducted. Piroxicam, like many other nonsteroidal anti-inflammatory drugs, inhibits the secondary phase of platelet aggregation and synthesis of prostaglandins, but unlike indomethacin and aspirin, piroxicam is a selective reversible inhibitor of the cyclo-oxygenase step of arachidonic acid metabolism. At usual therapeutic dosages piroxicam decreases synovial fluid concentrations of PGE1 and PGF in patients with rheumatoid arthritis. Piroxicam also influences certain immunological mechanisms and has been shown to decrease production of IgM rheumatoid factor in vitro and to decrease serum IgM rheumatoid factor in patients with rheumatoid arthritis. Piroxicam, unlike indomethacin and ibuprofen, inhibited Superoxide anion generation in vitro in stimulated polymorphonuclear cells. In vitro, piroxicam does not adversely affect the function of cartilage cells from dogs or humans.

Pharmacokinetic Properties: Following administration of single doses, the pharmacokinetics of piroxicam are linear. Maximum plasma concentrations are usually attained in about 2 hours, but may vary between 1 and 6 hours in different subjects. Steady-state concentrations are generally achieved in 7 to 12 days, with peak plasma concentrations ranging from 4.5 to 7.2 mg/L and trough concentrations from 3.9 to 5.6 mg/L after repeated doses of 20mg daily. Plasma concentrations 75% of those at steady-state are achieved by the second day when a loading dose of 40mg daily is administered for the first 2 days, but up to 8 days are needed to achieve this plasma concentration when a loading dose is not given. Omission of 1 day’s dosage after 7 days of continuous medication results in only a minimal fall in the plasma concentration of piroxicam. In contrast, plasma concentrations of diclofenac, indomethacin, and flurbiprofen decrease markedly under the same conditions. Piroxicam penetrates into the synovial fluid of patients with rheumatoid arthritis where concentrations are about 40% of those in plasma. Concentrations of piroxicam in breast milk are about 1% of those in maternal plasma at the same time.

Piroxicam is eliminated largely by biotransformation, the metabolites having little or no anti-inflammatory activity. The elimination half-life is extended due to a low systemic clearance rate and often ranges from 30 to 60 hours in healthy subjects. Pharmacokinetics are not age related and renal function has a limited influence on elimination of piroxicam, but plasma concentrations are increased in patients with severe liver insufficiency. There is no close association between plasma concentration or joint fluid concentration and therapeutic effect.

Therapeutic Trials: In patients with rheumatoid arthritis, piroxicam has been shown to be superior to placebo in practically all assessment criteria. Piroxicam 20mg daily was comparable with aspirin in maximum tolerated doses (2.65 to 6.3g daily) and with aloxiprin 4.8g daily. Studies comparing piroxicam with other non-steroidal anti-inflammatory drugs have generally indicated that piroxicam 20mg once daily or in divided doses is comparable in efficacy with indomethacin 75 to 200mg, ibuprofen 1200 and 2400mg daily, naproxen 500mg daily, diclofenac 75mg daily, ketoprofen 300mg daily, sulindac 400 to 800mg daily and phenylbutazone 400mg daily. As with other recently introduced non-steroidal drugs used in rheumatic diseases, piroxicam is better tolerated than aspirin, indomethacin or phenylbutazone. Long term open studies in rheumatoid arthritis have shown that the drug maintains its effectiveness for periods of up to 2 years.

Recently reported open multicentre trials involving several thousands of patients with rheumatoid arthritis have confirmed the effectiveness of piroxicam in alleviating pain and functional incapacity.

In patients with osteoarthritis, piroxicam 20mg daily was at least as effective as aspirin 2.6 to 3.9g daily, naproxen 500mg daily, diclofenac 150mg or fenbufen 600mg at night and comparable with indomethacin 75mg daily. In comparisons with controlled release indomethacin and diclofenac, piroxicam was at least as effective as diclofenac and appeared similar in efficacy to indomethacin. Piroxicam tended to be better tolerated than the controlled release preparations. Long term studies in adequate numbers of patients and short term trials in large groups of general practice patients have demonstrated that the effectiveness of the drug is maintained without an increase in dosage and that at a dosage of 20mg daily it is well tolerated by patients with osteoarthritis.

Piroxicam has been shown to be a suitable alternative to indomethacin in ankylosing spondylitis, and open trials in gout have been promising. However, further comparative trials are necessary to determine the role of piroxicam relative to that of established drugs in acute gout.

Placebo-controlled trials demonstrated the efficacy of piroxicam in acute musculoskeletal injuries, and comparative studies indicate that piroxicam 40mg daily for the first 2 days, reducing to 20mg thereafter, is generally similar in efficacy to indomethacin 75 to 150mg daily in the treatment of acute musculoskeletal disease. Piroxicam 20mg daily was superior to placebo in dysmenorrhoea and comparable with aspirin 648mg daily in relieving pain resulting from surgery or trauma.

Side Effects: The most frequently reported side effects have been gastrointestinal effects, but these have generally occurred less frequently with piroxicam than with therapeutically equivalent doses of aspirin, indomethacin or phenylbutazone. A survey of 73,000 patients treated with piroxicam indicated an overall side effect incidence of about 15%, with discontinuation of treatment necessary in about 5% of patients. Long term administration of doses of 30mg or higher is associated with an increased incidence of gastrointestinal side effects.

Dosage: The usual initial and maintenance dosage in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis is 20mg daily given as a single dose. In acute musculoskeletal disorders treatment should be started with 40mg daily for the first 2 days, then reduced to 20mg daily thereafter. The same dosage regimen is recommended in postoperative and post-traumatic pain when an onset of effect more rapid than that achieved with an initial dose of 20mg daily is required. Treatment of acute gout is started with a single 40mg dose and continued with 40mg daily.

Keywords

Rheumatoid Arthritis Indomethacin Ibuprofen Naproxen Piroxicam 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abe, T.: Piroxicam as a new adjunct for the treatment of rheumatoid arthritis. American Journal of Medicine 72(2A): 39–44 (1982).Google Scholar
  2. Abramson, S.; Edelson, H.; Kaplan, H.; Given, W. and Weissmann, G.: The neutrophil in rheumatoid arthritis: Its role and the inhibition of its activation by nonsteroidal antiinflammatory drugs. Seminars in Arthritis and Rheumatism 13 (Suppl. 1): 148–153 (1983).PubMedGoogle Scholar
  3. Abramson, S.; Edelson, H.; Kaplan, H.; Given, W. and Weissmann, G.: The inactivation of the polymorphonuclear leukocyte by non-steroidal anti-inflammatory drugs. Inflammation 8 (Suppl.): S103–S108 (1984).PubMedGoogle Scholar
  4. Abruzzo, J.L.; Gordon, G.V. and Meyers, A.R.: Double-blind study comparing piroxicam and aspirin in the treatment of osteoarthritis. American Journal of Medicine 72(2A): 45–49 (1982).Google Scholar
  5. Abruzzo, J.L.; Myers, A.R.; Schimmer, B.M. and Smukler, N.M.: Piroxicam in osteoarthritis: A double-blind 16 week study comparing piroxicam and aspirin. Presented at the XIV International Congress of Rheumatology, June 26-July 1, San Francisco, California, USA (1977).Google Scholar
  6. Abruzzo, J.L.; Sadeghian, M.R.; BeHoratius, R.J. and Smukler, N.M.: Piroxicam and aspirin in osteoarthritis: A double-blind and open study. Clinical Pharmacology and Therapeutics 25: 211 (1979).Google Scholar
  7. Aderounmu, A.F.; Walker, O. and Salako, L.A.: Controlled trial of piroxicam in osteoarthritis in Africans. Current Therapeutic Research 28: 888–893 (1980).Google Scholar
  8. Ali, S.: Piroxicam in the treatment of acute musculoskeletal disorders: Bangladesh multicentre study. Current Therapeutic Research 32: 574–578 (1982).Google Scholar
  9. Alvart, R.: Multicentre trial of piroxicam in ambulant rheumatology. European Journal of Rheumatology and Inflammation 6: 99–105 (1983).PubMedGoogle Scholar
  10. Ando, G.; Jellheden, B. and Sodergren, J.: Toleration of piroxicam. International Medicine 3: 37–41 (1983).Google Scholar
  11. Anslow, J.A.; Araujo, P.; Darke, A.; Hooper, J.W. and Martin, W.S.: Fecal blood loss with isoxicam or piroxicam for 28 days. Abstract. Clinical Pharmacology and Therapeutics 33: 217 (1983).Google Scholar
  12. Asiedu-Ofei, E.S. and Golding, J.R.: A double-blind crossover comparison of piroxicam mane and piroxicam nocte in osteoarthritis. European Journal of Rheumatology and Inflammation 4: 336–341 (1981).PubMedGoogle Scholar
  13. Avery, G.S.: Drug data information; in Avery (Ed.) Drug Treatment, 2nd ed., p.1211 (ADIS Press, Sydney 1980).Google Scholar
  14. Bachmann, F.: Correlation of plasma and synovial fluid concentrations of piroxicam in patients with rheumatoid arthritis; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980).Google Scholar
  15. Balant, L.; Gorgia, A.; Dayer, P.; Dupont, D. and Fabre, J.: Comportment du piroxicam chez l’homme en bonne sante et la malade en insuffisance renale. Rivista Medica Suizzica Italiana 6: 239–241 (1980).Google Scholar
  16. Balogh, Z.; Papazoglou, S.M.; MacLeod, M. and Buchanan, W.W.: A crossover clinical trial of piroxicam, indomethacin and ibuprofen in rheumatoid arthritis. Current Medical Research and Opinion 6: 148–153 (1979).PubMedGoogle Scholar
  17. Balogh, Z.; Papazoglou, S.; MacLeod, M. and Buchanan, W.W.: Crossover comparison of piroxicam versus placebo, indomethacin and ibuprofen in patients with rheumatoid arthritis. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp.10–14 (Academy Professional Information Services, New York 1980).Google Scholar
  18. Barbieri, E. and Greco, S.: Outpatient trials with a new non-steroidal anti-inflammatory drug on subjects suffering from osteoarthritis. International Journal of Tissue Reactions 2: 19 (1980).Google Scholar
  19. Bastos, A.C.; Bagnoli, V.R.; Fonseca, A.M.; Yamashita, S.A. and Celestino, CA.: Primary dysmenorrhoea: Efficacy and tolerance of piroxicam (data on file, Pfizer). Berry, H.; Bloom, B. and Hamilton, E.B.D.: A comparative study of piroxicam, diclofenac and placebo in osteoarthritis. Clinical Trials Journal 19: 349–358 (1982).Google Scholar
  20. Bertail, M.-A.; Cavelier, B. and Civatte, J.: Réaction au piroxicam a type d’ectodermose érosive pluri-orificielle. Annales de Dermatologie et de Vénéréologie 109: 261–262 (1982).PubMedGoogle Scholar
  21. Bianchine, J.R.; Procter, R.R. and Thomas, F.B.: Piroxicam, aspirin, and gastrointestinal blood loss. Clinical Pharmacology and Therapeutics 32: 247–252 (1982).PubMedGoogle Scholar
  22. Bluestone, R.H.: Safety and efficacy of piroxicam in the treatment of gout. American Journal of Medicine 72(2A): 66–69 (1982).Google Scholar
  23. Boardman, P.L.; Burke, M.J.; Camp, A.V. et al.: Treatment of osteoarthritis with piroxicam. European Journal of Rheumatology and Inflammation 6: 73–83 (1983).Google Scholar
  24. Bodem, H.; Haringer, E. and Maier-Lenz, H.: Open multicentre study comparing the efficacy and tolerability of diclofenac sodium and piroxicam in degenerative joint diseases. Presented at the 15th International Congress of Rheumatology, Paris (1981).Google Scholar
  25. Bontoux, D.; Xavier Phelip, A.G. and Fourtillan, J.-B.: Pharmacokinetics of piroxicam in synovial fluid, synovial membrane and cartilage; in The Rheumatological Disease Process: Focus on Piroxicam, Royal Society of Medicine International Congress and Symposium Series No. 67, pp.91-94 (1984).Google Scholar
  26. Box, J.; Box, P.; Turner, R. and Pisko, E.: Piroxicam and rheumatoid arthritis: A double-blind 16-week study comparing piroxicam and phenylbutazone. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.41-46 (1978).Google Scholar
  27. Brogden, R.N.; Pinder, R.M.; Speight, T.M. and Avery, G.S.: Fenoprofen: A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 13: 241–265 (1977a).PubMedGoogle Scholar
  28. Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Alclofenac: A review of its pharmacological properties and therapeutic efficacy in rheumatoid arthritis and allied rheumatic disorders. Drugs 14: 241 (1977b).PubMedGoogle Scholar
  29. Brogden, R.M.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Tolmetin: A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 15: 429 (1978a).PubMedGoogle Scholar
  30. Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Sulindac: A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 16: 97–114 (1978b).PubMedGoogle Scholar
  31. Brogden. R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Na-proxen up to date: A review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs 18: 241–277 (1979).PubMedGoogle Scholar
  32. Brogden, R.N.; Heel. R.C.; Pakes, G.E.; Speight, T.M. and Avery, O.S.: Diflunisal: A review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis. Drugs 19: 84–106 (1980).PubMedGoogle Scholar
  33. Brogden. R.N.; Heel. R.C.: Speight, T.M. and Avery, G.S.: Fenbufen: A review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain. Drugs 21: 1–22 (1981).PubMedGoogle Scholar
  34. Brosstad. F.: Laboratory safety in 1800 patients treated with piroxicam: in the Rheumatological Disease Process: Focus on Piroxicam. Royal Society of Medicine International Congress and Symposium Series No. 67. pp.59-63 (1984).Google Scholar
  35. Burry, H.C.; Treadwell, B.L.J. and Tweed, J.M.: Piroxicam in the management of rheumatoid arthritis: A comparison with naproxen. New Zealand Medical Journal 95: 352–354 (1982).PubMedGoogle Scholar
  36. Canadian Multicentre Study: Piroxicam vs indomethacin: A double blind multicentre comparative study in osteoarthritis. (In press. 1984).Google Scholar
  37. Cam. T.J.: Eskra. J.D.: Lombardino, J.G. and Hoffman, W.W.: Piroxicam. a potent inhibitor of prostaglandin production in cell culture. Structure-activity study. Prostaglandins 19: 51–59 (1980a).Google Scholar
  38. Carty. T.J.: Stevens. J.S.; Lombardino, J.G.; Parry, M.J. and Randall. M.J.: Piroxicam. a structurally novel anti-inflammatory compound. Mode of prostaglandin synthesis inhibition. Prostaglandins 19: 671–682 (1980b).PubMedGoogle Scholar
  39. Cash. H.C.; Humpston. D. and Kasap, H.S.: Feldene in the symptomatic treatment of primary dysmenorrhoea. Practitioner 226: 1338–1341 (1982).PubMedGoogle Scholar
  40. Ceuppens. J.L.: Rodriguez. M.A. and Goodwin, J.S.: Non-steroidal anti-inflammatory agents inhibit the synthesis of IgM rheumatoid factor in vitro. Lancet 1: 528–530 (1982).PubMedGoogle Scholar
  41. Chlud. K.; Pangerl. S.; Borde, H.; Siegmeth, W. and Lackner, M.: Relationship of piroxicam serum concentrations to clinical efficacy in rheumatoid arthritis. Proceedings of the 15th International Congress of Rheumatology, Paris, pp. 17–24 (1981).Google Scholar
  42. Clive. D.M. and Stoff. J.S.: Renal syndromes associated with nonsteroidal antiinflammatory drugs. New England Journal of Medicine 310: 563–572 (1984).PubMedGoogle Scholar
  43. Cobra. C.J.: Cobra. J.F. and Cobra Neto, C: Multicenter study with piroxicam in the treatment of osteoarthrosis involving 864 patients. Rev. Brasil. Clin. Terap. 11: 151–157 (1982).Google Scholar
  44. Cobra. C.J.: Cobra. J.F. and Cobra Neto, C: Use of piroxicam in the treatment of acute gout. European Journal of Rheumatology and Inflammation 6: 126–133 (1983).PubMedGoogle Scholar
  45. Collins. A.J. and Notarianni, L.J.: The acute action of fenbufen and piroxicam on the gastric mucosa as measured by gastric microbleeding. J. Int. Med. Res. 12: 179–183 (1984).PubMedGoogle Scholar
  46. Commandre. F.: Double-blind comparative study of piroxicam and indomethacin in acute locomotor affections linked with sports activity. European Journal of Rheumatology and Inflammation 6: 113–118 (1983).PubMedGoogle Scholar
  47. Co-operative Multicentre Canadian Trial: A double blind comparison of piroxicam and enteric-coated ASA in rheumatoid arthritis. Journal of Rheumatology (In press, 1984).Google Scholar
  48. Darragh, A.; Gordon, A.J.; O’Byrne, H.; Hobbs, D; Casey, E. and Lacey, P.: Single dose and steady state pharmacokinetics of piroxicam in elderly vs. young adults (data on file, Pfizer). Davies, J. and Dixon, A. St J.: Efficacy and safety of piroxicam compared with indomethacin in the management of rheumatoid arthritis. American Journal of Medicine 72(2A): 27–30 (1982).Google Scholar
  49. Davies, J.; Dixon, A. St J. and Ring, E.F.J.: A double-blind crossover comparison of piroxicam and indomethacin in the treatment of rheumatoid arthritis. European Journal of Rheumatology and Inflammation 4: 314–317 (1981).PubMedGoogle Scholar
  50. De Schepper, P.J.: Pharmacokinetics of piroxicam in man; in Management of Rheumatic Diseases, Manila Symposium, Excerpta Medica pp.21-33 (1982).Google Scholar
  51. De Schepper, P.J. and Heynen, G.: Pharmacokinetics of piroxicam in man, in The Rheumatological Disease Process: Focus on Piroxicam, Royal Society of Medicine International Congress and Symposium Series No. 67, pp.77-84 (1984).Google Scholar
  52. Dessain, P.: Efficacy and toleration of piroxicam in general practice: A multicenter study of osteoarthritis; in Advances in Arthritis Therapy. An International Review of Piroxicam, April, 1982. Postgraduate Medicine, Custom Communications, pp.76-81 (1982).Google Scholar
  53. Dessain, P.; Estabrooks, T.F. and Gordon, A.J.: Piroxicam in the treatment of osteoarthrosis: A multicentre study in general practice involving 1,218 patients. Journal of International Medical Research 7: 335 (1979).PubMedGoogle Scholar
  54. Di Perri, T.; Laghi, P.F.; Auteri, A.; Vittoria, A. and Messa, G.L.: Effect of a single dose of piroxicam on human platelet aggregation in vivo. International Journal of Tissue Reactions 1: 161–162 (1979).Google Scholar
  55. De Vere-Tyndall, A.G.; Ansel, B.M.; Piper, S. and Lyanage, S.: Piroxicam in synovial fluid; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam, pp.52–53 (Excerpta Medica, Princeton 1980).Google Scholar
  56. De Zubiria, R.C.; Charria, A. and Guerrero, D.L.: Clinical and laboratory changes produced by piroxicam in rheumatoid arthritis. European Journal of Rheumatology and Inflammation 6: 56–62 (1983).PubMedGoogle Scholar
  57. Dixon, A. St J. and Davies, J.: A double-blind, crossover comparison of piroxicam and indomethacin in the treatment of rheumatoid arthritis. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp. 14–22 (Academy Professional Information Services, New York 1980).Google Scholar
  58. Edwards, V.; Wilson, A.A.; Hanvood, H.F.; Manning, S.I.; Brabbin, W.; Walker, J.W. et al.: A multicentre comparison of piroxicam and indomethacin in acute soft tissue sports injuries. Journal of International Medical Research 12: 46–50 (1984).PubMedGoogle Scholar
  59. Emery, P. and Grahame, R.: Gastrointestinal blood loss and piroxicam. Lancet 1: 1302–1303 (1982).PubMedGoogle Scholar
  60. Faure, M.; Goujon, G and Perrot, H.: Accidents cutanés provoquis par le piroxicam. A propes de trois observations. Annales de Dermatologie et de Vénérérologie 109: 255–258 (1982).Google Scholar
  61. Filho, J.L.: Multicenter study of piroxicam in the treatment of acute musculoskeletal diseases involving 3011 patients. Europ. J. Rheumatol. Inflam. 6: 119–125 (1983).Google Scholar
  62. Finstad, R.: A double-blind, crossover, multicentre study of piroxicam and indomethacin in the treatment of rheumatoid arthritis. British Journal of Clinical Practice 35: 35–39 (1981).PubMedGoogle Scholar
  63. Flouvat, B.: Pharmacologic properties and pharmacokinetic pattern of piroxicam, a new anti-inflammatory agent. Proceedings of the 15th International Congress of Rheumatology, Paris, pp.l-16,(1981).Google Scholar
  64. Fourtillan, J.-B. and Dubourg, D.: Pharmacokinetics of piroxicam with multiple dosing. Comparison between two dosage regimens; in The Rheumatological Disease Process: Focus on Piroxicam, Royal Society of Medicine, International Congress and Symposium Series No. 67, pp.85-89 (1984).Google Scholar
  65. Fowler, R.W. and Arnold, K.G.: Non-steroidal analgesic and antiinflammatory agents. British Medical Journal 287: 835 (1983).PubMedGoogle Scholar
  66. Førre, Ø.; Thoen, J.; Helgetveit, K. and Haile, Y.: Nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Effects on clinical parameters and cellular immunity. Inflammation 8 (Suppl.): S109–S113 (1984).PubMedGoogle Scholar
  67. Frais, M.A.; Burgess, E.D. and Mitchell, L.B.: Piroxicam-induced renal failure and hyperkalaemia. Annals of Internal Medicine 99: 129–130 (1983).PubMedGoogle Scholar
  68. Gallacchi, G. and Strolz, F.: Clinical evaluation of ‘Osmosin’ versus piroxicam. Current Medical Research and Opinion 8 (Suppl. 2): 83–89 (1983).PubMedGoogle Scholar
  69. Garcia de la Torre, I.: A comparative study of piroxicam and sulindac in the treatment of rheumatoid arthritis. Current Therapeutic Research 35: 130–134 (1984).Google Scholar
  70. Gaynor, G.J. and Constantine, J.W.: Effect of piroxicam on platelet aggregation. Experientia 35: 797 (1979).PubMedGoogle Scholar
  71. Ginsberg, F.; Appelboom, T. and Famaey, J.P.: Efficacy and safety of piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. Current Therapeutic Research 28: 570 (1980).Google Scholar
  72. Giordano, M.G.; Baptista, CF.; Guerreiro, E.M.T.; Bravo, I.L.P.; Moreira, A.J. and Costa, O.T.: Piroxicam in the treatment of patients affected with primary dysmenorrhoea (data on file, Pfizer). Goebel, K.M. and Mueller-Brodmann, W.: Reversible overt nephropathy with Henoch-Schönlein purpura due to piroxicam. British Medical Journal 284(6312): 311–312 (1982).Google Scholar
  73. Goldie, I.F.: Piroxicam and naproxen in osteoarthritis: A clinical comparison. European Journal of Rheumatology and Inflammation 4: 342–356 (1981).Google Scholar
  74. Goldie, I.V.: Piroxicam and naproxen in osteoarthritis. A clinical comparison. American Journal of Medicine 72(2A): 50–53 (1982).Google Scholar
  75. Goldman, D.: Management of chronic backache. Proceedings of the 15th International Congress of Rheumatology, Paris, pp.99-102 (1981).Google Scholar
  76. González, R.: Uso de piroxicam en el tratamiento de las lesiones musculoesqueléticas agudas. Investigacion Medica International 10: 132–134 (1983).Google Scholar
  77. Goodwin, J.S. and Ceuppens, J.L.: Effect of nonsteroidal antiinflammatory drugs on immune function. Seminars in Arthritis and Rheumatism 13 (Suppl. 1): 134–143 (1983).PubMedGoogle Scholar
  78. Goodwin, J.S.; Ceuppens, J.L. and Rodriguez, M.A.: Administration of nonsteroidal anti-inflammatory agents in patiens with rheumatoid arthritis. Journal of the American Medical Association 250: 2485–2488 (1983).PubMedGoogle Scholar
  79. Goodwin, J.S.; Ceuppens, J.L. and Rodriguez, M.A.: Inhibition of rheumatoid factor production by non-steroidal anti-inflammatory drugs. Inflammation 8 (Suppl.): S49–S55 (1984).PubMedGoogle Scholar
  80. Gordon, A.J.; Estabrooks, T.F. and Dessain, P.: Treatment of osteoarthrosis with piroxicam in general practice: Long-term follow-up in a multicentre study. Journal of International Medical Research 8: 375 (1980a).PubMedGoogle Scholar
  81. Gordon, D. and Lewis, G.P.: Effects of piroxicam on mononuclear cells: Comparison with other antiarthritic drugs. Inflammation 8 (Suppl.): S87–S102 (1984).PubMedGoogle Scholar
  82. Gordon, G.V.: Q.D. versus B.I.D. therapy in rheumatoid and osteoarthritis. Paper presented at the American Academy of Family Practitioners Meeting, Miami, October (1983).Google Scholar
  83. Gordon, V.; Abruzzo, J.L.; Myers, A.R. and Boyle, J.A.: A double-blind parallel group multicenter comparison of piroxicam and aspirin in patients with osteoarthritis; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980b).Google Scholar
  84. Gow, P.J.: A multi-centre study of piroxicam in the treatment of osteoarthritis and rheumatoid arthritis in general practice. Current Medical Research and Opinion 8: 618–621 (1983).PubMedGoogle Scholar
  85. Grewin, B.: Piroxicam in rheumatoid arthritis. International Journal of Tissue Reactions 1: 163–166 (1979).Google Scholar
  86. Grewin, B.: Piroxicam in the treatment of rheumatoid arthritis. European Journal of Rheumatology and Inflammation 4: 332–335 (1981).PubMedGoogle Scholar
  87. Grossman, L.A. and Moss, S.: Piroxicam and hyperkalemic acidosis. Annals of Internal Medicine 99: 282 (1983).PubMedGoogle Scholar
  88. Gunther, R.; Egg, D. and Herold, M.: Efficacy and safety of piroxicam and indomethacin in the treatment of musculoskeletal disorders —A double blind comparative study. Zeitschrift für Rheumatologie 38: 330 (1979).PubMedGoogle Scholar
  89. Halsey, J.P.; Fitzcharles, M.A. and Currey, H.L.F.: Piroxicam in ankylosing spondylitis. European Journal of Rheumatology and Inflammation 4: 364–367 (1981).PubMedGoogle Scholar
  90. Herman, J.H.; Appel, A.M.; Khosla, R.C; Kelch, K.S. and Hess, E.V.: Cytokine modulation of chondrocyte metabolism —In vivo and in vitro effects of piroxicam. Inflammation 8 (Suppl.): S125–S137 (1984).PubMedGoogle Scholar
  91. Hess, H.; Rothaar, J. and Thiel, W.: Therapy of acute sports injuries with a new antiarthritic agent, piroxicam; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980).Google Scholar
  92. Heynen, G.: A double-blind placebo-controlled trial of piroxicam in 591 patients with osteoarthritis; in The Rheumatological Disease Process: Focus on Piroxicam, Royal Society of Medicine International Congress and Symposium Series No. 67, pp. 19–22 (1984).Google Scholar
  93. Heynen, G. and Dessain, P.: Piroxicam suppositories for osteoarthritis and rheumatoid arthritis: An open multicentre study in 116 patients. European Journal of Rheumatology and Inflammation 6: 134–138 (1983).PubMedGoogle Scholar
  94. Hobbs, D.C.: Pharmacokinetics of piroxicam in man. European Journal of Rheumatology and Inflammation 6: 46–55 (1983).PubMedGoogle Scholar
  95. Hobbs, D.C. and Gordon, A.J.: Absence of effect of age on the pharmacokinetics of piroxicam; in The Rheumatological Disease Process: Focus on Piroxicam, Royal Society of Medicine International Congress and Symposium Series No. 67, pp.99-101 (1984).Google Scholar
  96. Hobbs, D.C. and Twomey, T.M.: Piroxicam pharmacokinetics in man: Aspirin and antacid interaction studies. Journal of Clinical Pharmacology 19: 270–281 (1979).PubMedGoogle Scholar
  97. Ishizaki, T.; Nomura, T. and Abe, T.: Pharmacokinetics of piroxicam, a new non-steroidal anti-inflammatory agent, under fasting and postprandial states in man. Journal of Pharmacokinetics and Biopharmaceutics 7: 369–381 (1979).PubMedGoogle Scholar
  98. Ishizaki, T.; Sasaki, T.; Suganuma, T.; Horai, Y.; Chiba, K.; Watanabe, M.; Asuke, W. and Hoshi, H.: Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. European Journal of Clinical Pharmacology 18: 407–414 (1980).PubMedGoogle Scholar
  99. Iwegbu, CG.; Patel. R.J.; McLeod, P. and Helal, B.: A double-blind comparison of piroxicam mane with piroxicam nocte in patients awaiting hip and/or knee joint replacement. European Journal of Rheumatology and Inflammation 4: 342–347 (1981).PubMedGoogle Scholar
  100. Jacotot, B.: Interaction study of piroxicam with oral anticoagulants. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp.46–48 (Academy Professional Information Services, New York 1980).Google Scholar
  101. Jain, A.K.; McMahon, F.G.; Ryan, J.R.; Raphan, H. and Richard, W.: Piroxicam, a novel analgesic in post-partum pain. European Joural of Rheumatology and Inflammation 356–359 (1978).Google Scholar
  102. Janke, P.; Williams, P.; Williams, P. and Diggins, J.B.: Sulindac versus piroxicam in the treatment of osteoarthritis. Current Medical Research and Opinion 8: 434–440 (1983).PubMedGoogle Scholar
  103. Jansen, W.: Effect of piroxicam on renal function in geriatric patients with osteoarthritis. Proceedings of the 15th International Congress of Rheumatology, Paris, pp.37-42 (1981).Google Scholar
  104. Jeanmougin, M.; Ribrioux, A.; Janier, M. et al.: Pemphigus séborrhéique au cours d’une polyarthrite rheumatoide traitée par D’penicillamine puis par piroxicam. Annales de Dermatologie et de Vénéréologie 110: 476 (1983).Google Scholar
  105. Julkunen, H.; Michelsson, J.-E. and Mattila, M.J.: Pain relief in relation to tissue piroxicam concentrations in hip osteoarthritis. Annals of Clinical Research 15: 99–103 (1983).PubMedGoogle Scholar
  106. Kaplan, H.B.; Edelson, H.S.; Korchak, H.M.; Given, W.P.; Abramson, S. and Weissmann, G.: Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo. Biochemical Pharmacology (In press 1984).Google Scholar
  107. Katona, G. and Burgos Vargas, R.: Piroxicam en osteoarthritis Experiencia a corto y largo plazo. Investigacion Medica Internacional 10: 78–83 (1983).Google Scholar
  108. Katona, G.; Burgos, R. and Zimbron, A.: Sequential quantitative joint scintigraphy in the investigation of anti-inflammatory effects of piroxicam. European Journal of Rheumatology and Inflammation 6: 63–72 (1983).PubMedGoogle Scholar
  109. Kerry, R.J.; Owen, G. and Michaelson, S.: Possible toxic interaction between lithium and piroxicam. Lancet 1: 418–419 (1983).PubMedGoogle Scholar
  110. Kniisel, O.: Piroxicam in der Therapie von Arthrose und Weichteilrheumatismus. Schweizerische Rundschau für Medizin Praxis 70: 2316–2321 (1981).Google Scholar
  111. Kogstad, O.: Double blind crossover trial of piroxicam and naproxen in the treatment of osteoarthritis of hip and knee. British Journal of Clinical Practice 35: 45–50 (1981).PubMedGoogle Scholar
  112. Krame, G. and Han, O.: Empleo de un nuevo anti-inflamatorio no esteroideo en el tratamiento de lesiones deportivas. Investigacion Medica Internacional 8: 255–258 (1981).Google Scholar
  113. Laake, K.; Kjeldaas, L. and Borchgrevink, CF.: Side effects of piroxicam (Feldene). Acta Medica Scandinavica 215: 81–83 (1984).PubMedGoogle Scholar
  114. Langloh, N.: Experience with piroxicam in general practice: Results of a German multicentre study on 18,888 patients. European Journal of Rheumatology and Inflammation 6: 84–89 (1983).PubMedGoogle Scholar
  115. Larson, D.L.; Antognoli, G.W. and Carty, T.J.: The ocular antiinflammatory activity of topical piroxicam. Ophthalmology 89: S182 (1982).Google Scholar
  116. Larson, D.L. and Lombardino, J.G.: The topical anti-inflammatory effects of piroxicam in rodents. Agents and Action 10: 246 (1980).Google Scholar
  117. Laufen, H.; Leitold, M. and Riedel, K.-D.: The effect of activated charcoal on the gastrointestinal absorption and reabsorption of piroxicam in man (data on file, Pfizer). Lederman, R.: An epidemiological and therapeutic multicenter study involving 3,309 patients with osteoarthritis. European Journal of Rheumatology and Inflammation 6: 90–98 (1983).Google Scholar
  118. Lee, S.H.; Fawcett, V. and Preece, J.M.: Aplastic anaemia associated with piroxicam. Lancet 1: 1186 (1982).PubMedGoogle Scholar
  119. Lee, H.K.; Hong, J.Y.; Lee, S.H. and Song, H.S.: Clinical effects of piroxicam in orthopedic field. Korean Central Journal of Medicine 36: 425–429 (1979).Google Scholar
  120. Lereim, P. and Gabor, I.: Piroxicam in acute musculoskeletal disorders; in The Rheumatological Disease Process: Focus on Piroxicam, Royal Society of Medicine International Congress and Symposium Series No. 67, pp.49-51 (1984).Google Scholar
  121. Lingetti, M.; Bianchi, A.; Ciarimboli, M. and Policicchio, D.: Blood levels and onset of analgesic activity after short-term administration of piroxicam and ibuprofen, and effect of piroxicam on gastrin secretion; in Dessain (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam, pp.35–40 (Excerpta Medica, Amsterdam 1980).Google Scholar
  122. Lo, G.C.C. and Chan, J.Y.W.: Piroxicam poisoning. British Medical Journal 287: 798 (1983).PubMedGoogle Scholar
  123. Lochead, J.A. and Baragar, F.D.: A comparative study of piroxicam and enteric coated acetylsalicylic acid in rheumatoid arthritis: A co-operative multicentre trial. Abstract 271. Arthritis and Rheumatism 25 (April Suppl.): 48 (1982).Google Scholar
  124. Lombardino, J.G. and Wiseman, E.H.: Sudoxicam and related Nheterocyclic carboxamides of 4-hydroxy-2H-l,2-benzothiazine, 1,1-dioxide. Potent non-steroidal anti-inflammatory agents. Journal of Medicinal Chemistry 15: 848–849 (1972).PubMedGoogle Scholar
  125. Lombardino, J.F. and Wiseman, E.H.: Potent anti-inflammatory N-heterocyclic 3-carboxamides of 4-hydroxy-2-methyl-2H-l,2-benzothiazine 1,1-dioxide. Journal of Medicinal Chemistry 16: 493–496 (1973).PubMedGoogle Scholar
  126. Londono, F. and Gaitán, G.: Piroxicam en lesiones musculoesqueleticas agudas. Estudio cooperativo. Investigacion Medica Internacional 10: 422–424 (1983).Google Scholar
  127. Lopes Vaz, A.: Piroxicam in the treatment of ankylosing spondylitis. Proceedings of the 15th International Congress of Rheumatology, Paris pp.95-98 (1981).Google Scholar
  128. McAdam, L.P.; O’Hanlan, M.A. and Willkens, R.F.: Piroxicam in ankylosing spondylitis: A 14-week controlled double-blind study comparing piroxicam to phenylbutazone. Proceedings of the 15th International Congress of Rheumatology, Paris, pp.87-94 (1981).Google Scholar
  129. Maccagno, A.: Piroxicam in the treatment of acute musculoskeletal disorders; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980).Google Scholar
  130. Makisara, P. and Nuotio, P.: Piroxicam and rheumatoid arthritis: Comparative study of piroxicam and ibuprofen. Royal Society of Medicine, International Congress and Symposium Series No. 1, pp.65-70 (1078).Google Scholar
  131. Manahan, L.A. and Dominguez, C: Piroxicam in osteoarthritis. Philippine Journal of International Medicine 18: 125 (1980).Google Scholar
  132. Martin, R.L.; McSweeney, G.W. and Schneider, J.: Fatal pemphigus vulgaris in a patient taking piroxicam. New England Journal of Medicine 309: 795–796 (1983).PubMedGoogle Scholar
  133. Mbuyi-Muamba, J.M. and Dequeker, J.: Piroxicam versus naproxen in rheumatoid arthritis. Current Medical Research and Opinion 8: 612–617 (1983).PubMedGoogle Scholar
  134. Menck-Thygesen, H.; Ibfelt, H.-H.; Porsman, O. and Fano, N.: Double-blind crossover study of piroxicam versus naproxen in osteoarthritis; in The Rheumatological Disease Process: Focus on Piroxicam. Royal Society of Medicine International Congress and Symposium Series No 67, pp.7-11 (1984).Google Scholar
  135. Mercier, M. and Lesne, M.: The pharmacokinetics of piroxicam and indomethacin; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980).Google Scholar
  136. Milne, G.M. and Twomey, T.M.: The analgetic properties of piroxicam in animals and correlation with experimentally determined plasma levels. Agents and Actions 10: 1/2 (1980).Google Scholar
  137. Mitnick, P.D. and Klein, W.J.: Piroxicam-induced renal disease. Archives of Internal Medicine 144: 63–64 (1984).PubMedGoogle Scholar
  138. Mohr, W.; Kirkpatrick, C.J.; Wildfeuer, A. and Leitold, M.: Der einfluss von Piroxicam auf Struktur und Funktionen des Gelenkknorpels. Zeitschrift für Rheumatologie 42: 70–77 (1983).PubMedGoogle Scholar
  139. Mohr, W.; Kirkpatrick, C.J.; Wildfeuer, A. and Leitold, M.: Effect of piroxicam on structure and function of joint cartilage. Inflammation 8 (Suppl.): S139–S154 (1984).PubMedGoogle Scholar
  140. Muller-Fassbender, H. and Schattenkirchner, M.: Piroxicam in ankylosing spondylitis: An open study. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.83-92 (1978).Google Scholar
  141. Muller-Fassbender, H.H. and Nagel, E.: Comparative study of piroxicam and indomethacin retard in osteoarthritis. European Journal of Rheumatology and Inflammation 6: 102–112 (1983).Google Scholar
  142. Murphy, J.E.: Piroxicam in the treatment of acute gout: A multicentre open study in general practice. Journal of International Medical Research 7: 507 (1979).PubMedGoogle Scholar
  143. Nash, J.F.; Bechtol, L.D.; Bunde, CA.; Bopp, R.J.; Farid, K.Z. and Spradlin, CT.: Linear pharmacokinetics of orally administered fenoprofen calcium. Journal of Pharmaceutical Sciences 68: 1087–1090 (1979).PubMedGoogle Scholar
  144. Neuman, M.: A clinical and pharmacokinetic study of piroxicam administered as a rectal suppository. Drugs in Experimental and Clinical Research 7: 15 (1981).Google Scholar
  145. Noguchi, Y.; Ishiko, J. and Ohtsuki, I.: Comparative pharmacological profiles of piroxicam, indomethacin, phenylbutazone, diclofenac, ibuprofen and mefenamic acid; in The Rheumatological Disease Process: Focus on Piroxicam, The International Congress and Symposium Series No. 67, pp.69-75 (1984).Google Scholar
  146. Norris, E.; Jellheden, B. and Sodergren, J.: Toleration of piroxicam: A review of worldwide clinical experience. Paper presented at the 5th Seapal Congress, Bangkok, January (1984).Google Scholar
  147. Nuotio, P. and Makisara, P.: Pharmacokinetic and clinical study of piroxicam. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.25-30 (1978).Google Scholar
  148. Nussdorf, R.T.: Piroxicam in acute musculoskeletal disease: A double-blind 14 day study comparing piroxicam and phenylbutazone. Presented in the XIV International Congress of Rheumatology, June 26–July 1, San Francisco, USA (1977).Google Scholar
  149. Østensen, M.: Piroxicam in human breast milk. European Journal of Clinical Pharmacology 25: 829–830 (1983).PubMedGoogle Scholar
  150. Ostermann, K.: A double blind comparative study of piroxicam and indomethacin in osteoarthrosis; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980).Google Scholar
  151. Österman, K.: Piroxicam versus slow-release diclofenac in osteoarthritis; in the Rheumatological Disease Process: Focus on Piroxicam, Royal Society of Medicine International Congress and Symposium Series No. 67, pp.13-17 (1984).Google Scholar
  152. Otte, J.: Long term efficacy of piroxicam in osteoarthrosis; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980).Google Scholar
  153. Otterness, I.G.; Larson, D.L. and Lombardino, J.G.: An analysis of piroxicam (Feldene) in rodent models of arthritis. Agents and Actions 12: 308–312 (1982).PubMedGoogle Scholar
  154. Pastore, R. and Gullo, D.: Clinical trial on the use of piroxicam in the therapy of dysmenorrhea. Contraccezione Fertilita Sessualita 7: 85–88 (1980).Google Scholar
  155. Perrand, J.; Stadler, J.; Kessedjian, M.J. and Munro, A.M.: Reproductive studies with the anti-inflammatory agent, piroxicam: Modification of classical protocols. Toxicology 30: 59–63 (1984).Google Scholar
  156. Pisko, E.J.; Rahman, M.A.; Turner, R.A. and Agudelo, CA.: Long term efficacy and safety of piroxicam in the treatment of rheumatoid arthritis. Current Therapeutic Research 27: 852–859 (1980).Google Scholar
  157. Pitts, N.E.: Review of clinical trial experience with piroxicam. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp.48–66 (Academy Professional Information Services, New York 1980).Google Scholar
  158. Pitts, N.E. and Proctor, R.R.: Summary: Efficacy and safety of piroxicam. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.97-108 (1978).Google Scholar
  159. Pulliam, J.P.; Mundis, R.J. and Muther, R.S.: Piroxicam (Feldene) predisposes to chemotherapy-induced acute uric acid nephropathy. Arthritis and Rheumatism 27: 116–117 (1984).PubMedGoogle Scholar
  160. Radi, I.: Double-blind comparison of piroxicam and indomethacin in patients with osteoarthrosis. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp.32–37 (Academy Professional Information Services, New York 1980).Google Scholar
  161. Radi, I.; Matoso, L.; Posmantir, A. and Papalexiou, P.: Safety and efficacy of piroxicam in the treatment of ankylosing spondylitis. European Journal of Rheumatology and Inflammation 1: 349–351 (1978).Google Scholar
  162. Rau, R.: Interaction study of piroxicam with digoxin. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp.41–46 (Academy Professional Information Services, New York 1980).Google Scholar
  163. Reubi, F.: Lack of effect of piroxicam on renal function. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp. 37–41 (Academy Professional Information Services, New York 1980).Google Scholar
  164. Roberts, S.D.; Vir, C. and Porter, K.G.: Once-daily piroxicam in rheumatoid arthritis: A double-blind crossover comparison with aloxiprin. European Journal of Rheumatology and Inflammation 4: 323–331 (1981).PubMedGoogle Scholar
  165. Rogers, H.J.: The pharmacokinetics of piroxicam and flurbiprofen; in Boyle (Ed.) Rheumatology in the Eighties: An Advance in Therapy —Piroxicam (Excerpta Medica, Princeton 1980).Google Scholar
  166. Rogers, HJ.; Spector, R.G.; Morrison, P.J. and Bradbrook, I.D.: Comparative steady state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects. European Journal of Rheumatology and Inflammation 4: 303–308 (1981).PubMedGoogle Scholar
  167. Rohde, J.; Schwegler, F. and Standel, W.: Treatment of rheumatoid arthritis. Open parallel study with the non-steroidal antirheumatics piroxicam and diclofenac. Deutsche Medizin-ische Wochenschrift 105: 1614–1617 (1980).Google Scholar
  168. Romberg, O.: Comparison of piroxicam with indomethacin in ankylosing spondylitis. A double-blind crossover trial. American Journal of Medicine 72(2A): 58–62 (1982).Google Scholar
  169. Sachs, R.: Phototoxic reactions to piroxicam and other non-steroidal anti-inflammatory drugs. New England Journal of Medicine 309: 187 (1983).Google Scholar
  170. Saltveit, T.: Piroxicam in primary dysmenorrhoea (data on file, Pfizer). Santilli, G.; Tuccimei, U. and Cannistra, F.M.: Comparative study with piroxicam and ibuprofen versus placebo in the supportive treatment of minor sports injuries. Journal of International Medical Research 8: 265–269 (1980).Google Scholar
  171. Schattenkirchner, M.; Muller-Fassbender, H. and Melzer, H.: An open long-term study of piroxicam in ankylosing spondylitis patients. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp.28–32 (Academy Professional Information Services, New York 1980).Google Scholar
  172. Schattenkirchner, M.; Muller-Fassbender, H.; Melzer, H. and Henze, K.: Effectiveness of piroxicam in the treatment of patients with ankylosing spondylitis. An open long-term study. American Journal of Medicine 72(2A): 54–57 (1982).Google Scholar
  173. Scheinberg, M.A.; Rueda, H. and Mathews, P.C.: The effect of piroxicam on neutrophil and monocyte macrophage function. European Journal of Rheumatology and Inflammation 6: 36–40 (1983).PubMedGoogle Scholar
  174. Schiantarelli, P.; Acerbi, D. and Bovis, G.: Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man. Arzneimittel-Forschung 31: 92–97 (1981).PubMedGoogle Scholar
  175. Schiantarelli, P. and Cadel, S.: Piroxicam: Pharmacologie activity and gastrointestinal damage by oral and rectal route. Arzneimittel-Forschung 31: 87–91 (1981).PubMedGoogle Scholar
  176. Schoog, M.: Pharmacokinetics of piroxicam in comparison with plain diclofenac and diclofenac slow release: A cross-over study in normal volunteers. Paper presented at a Round Table Discussion on Piroxicam, at Brussels on May 30 (1980).Google Scholar
  177. Schoog, M.; Laufen, H. and Dessain, P.: A comparison of the pharmacokinetics of piroxicam with those of plain and slow release indomethacin: A crossover study. European Journal of Rheumatology and Inflammation 4: 298–302 (1981).PubMedGoogle Scholar
  178. Schulman, H.; Duvivier, R. and Blattner, P.: The uterine contractility index: A research and diagnostic tool in dysmenorrhea. American Journal of Obstetrics and Gynaecology (April) pp. 1049–1058 (1983).Google Scholar
  179. Shichikawa, K.: Double-blind evaluation of piroxicam in the treatment of rheumatoid arthritis. A standardised approach to new drug evaluation in Japan. Proceedings of a Pfizer Forum: The Management of Rheumatic Diseases; Excerpta Medica Asia Pacific Congress Series No. 10, pp.34-45 (1982).Google Scholar
  180. Shivarov, S.N. and Akar, P.E.: An open evaluation of piroxicam (Feldene) in osteoarthrosis. Current Therapeutic Research 28: 639–645 (1980).Google Scholar
  181. Siegmeth, W.: Serum concentrations of piroxicam in relation to its clinical effect in patients with chronic polyarthritis. Wiener Medizinische Wochenschrift, Special issue, pp.31-35 (1980).Google Scholar
  182. Smyth, C.J. and Bravo, J.F.: Antirheumatic drugs: Clinical pharmacological and therapeutic aspects. Drugs 10: 394–425 (1975).PubMedGoogle Scholar
  183. Spector, S.L.; Morris, H.G. and Seiner, J.C.: Pulmonary, prostaglandin and clinical response of asthmatic patients with aspirin idiosyncrasy to a new nonsteroidal anti-inflammatory substance compared to aspirin. Journal of Allergy and Clinical Immunology 63: 154–155 (1979).Google Scholar
  184. Spector, S.L.; Morris, H.G. and Seiner, J.C.: Clinical response and serum prostaglandin levels in aspirin idiosyncrasy. Effect of aspirin and a new nonsteroidal anti-inflammatory agent. Chest 80: 676–681 (1981).PubMedGoogle Scholar
  185. Steelman, S.L.; Tempero, K.F. and Cirillo, V.J.: The chemistry, pharmacology, toxicology and clinical pharmacology of diflunisal. Clinical Therapeutics 1 (Suppl. 1): 1–9 (1978).Google Scholar
  186. Steigerwald, J.C.: Piroxicam and rheumatoid arthritis: A double-blind 16-week study comparing piroxicam and indomethacin. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.47-52 (1978).Google Scholar
  187. Stern, R.S.: Phototoxic reactions to piroxicam and other non-steroidal anti-inflammatory agents. New England Journal of Medicine 309: 186–187 (1983).PubMedGoogle Scholar
  188. Stravinski, S.: Piroxicam analgesia, in Advances in Arthritis Therapy. An International Review of Piroxicam, April 1982. Postgraduate Medicine, Custom Communications (1982).Google Scholar
  189. Strusberg, A.; Montrull, H. and Meirovich, C.I.: Anti-prostaglandin and anti-inflammatory short-term efficacy of piroxicam in rheumatoid arthritis. European Journal of Rheumatology and Inflammation 6: 41–45 (1983).PubMedGoogle Scholar
  190. Sydnes, O.A.: Comparison of piroxicam with naproxen in rheumatoid arthritis: A double-blind, cross-over, multicentre study. European Journal of Rheumatology and Inflammation 4: 318–322 (1981a).PubMedGoogle Scholar
  191. Sydnes, O.A.: Comparison of piroxicam with indomethacin in ankylosing spondylitis: A double-blind crossover trial. British Journal of Clinical Practice 35: 40–44 (1981b).PubMedGoogle Scholar
  192. Sydnes, O.A.: Double-blind comparison of piroxicam and naproxen in the management of rheumatoid arthritis. American Journal of Medicine 72(2A): 31–33 (1982).Google Scholar
  193. Tausch, G.: Speed of onset and duration of action of piroxicam in patients with rheumatoid arthritis: A placebo-controlled study. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at IXth European Congress of Rheumatology, Sept 4, 1979, pp.22–28 (Academy Professional Information Services, New York 1980).Google Scholar
  194. Tausch, G.: Placebo-controlled study of piroxicam in the treatment of rheumatoid arthritis. American Journal of Medicine 72(2A): 18–22 (1982).Google Scholar
  195. Tausch, G. and Eberl, R.: Efficacy, tolerance and safety of piroxicam in the treatment of acute gout. European Journal of Rheumatology and Inflammation 1: 365–368 (1978).Google Scholar
  196. Tausch, G.; Eberl, R. and Bröll, H.: Piroxicam and rheumatoid arthritis: Long-term open treatment. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.59-64 (1978).Google Scholar
  197. Telhag, H.: Piroxicam in safety and efficacy of the treatment of osteoarthritis. European Journal of Rheumatology and Inflammation 1: 352–355 (1978).Google Scholar
  198. Tempero, K.F.; Cirilli, V.J. and Steelman, S.L.: Diflunisal: A review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans. British Journal of Clinical Pharmacology 4 (Suppl. 1): 31 (1977).Google Scholar
  199. Tilstone, W.J.; Lawson, D.H.; Omara, F. and Cunningham, F.: The steady-state pharmacokinetics of piroxicam: Effects of food and iron. European Journal of Rheumatology and Inflammation 4: 309–313 (1981).PubMedGoogle Scholar
  200. Turner, R.; April, P.A. and Robbins, D.L.: A double-blind multicenter study comparing piroxicam and ibuprofen in the treatment of rheumatoid arthritis. American Journal of Medicine 72(2A): 34–38 (1982).Google Scholar
  201. Twomey, T.M.; Bartobucci, S.R. and Hobbs, D.C.: Analysis of piroxicam in plasma by high-performance liquid chromatography. Journal of Chromatography 183: 104–108 (1980).PubMedGoogle Scholar
  202. Twomey, T.M. and Hobbs, D.C.: Biotransformation of piroxicam by man. Federation Proceedings 37: 271 (1978).Google Scholar
  203. Ulloa, J.E. and Mar, M.: Estudio clinico comparativo de piroxicam vs diclofenac ‘retard’ en gonartrosis. Investigacion Medica Internacional 10: 417–421 (1983).Google Scholar
  204. Upton, R.A.; Buskin, J.N.; Williams, R.L; Holford, N.H.G. and Riegelman, S.: Negligible excretion of unchanged ketoprofen, naproxen and probenecid in urine. Journal of Pharmaceutical Sciences 69: 1254–1257 (1980).PubMedGoogle Scholar
  205. Verbruggen, G.E.M.; Veys, P.; Hermanns, J.; Delange, J. and Vansteen Kiste, M.: The effect of low doses of prednisolone on the traffic of T helper-inducer cells in rheumatoid arthritis. Clinical Rheumatology 1: 199–207 (1982).PubMedGoogle Scholar
  206. Veys, E.; Verbruggen, G.; Suykens, S.; Mielants, H.; Ackerman, K.; Van Lerbeirghe, J. and Heynen, G.: Lymphocyte subpopulation counts after a single 40mg administration of piroxicam in 20 patients with rheumatoid arthritis: A placebo controlled study. Inflammation 8 (Suppl.): S115–S122 (1984).PubMedGoogle Scholar
  207. Villegas, S.; Barreto, R.A. and Crespo-Vásquez, A.: Evaluación de piroxicam en pacientes con gonartrosis. Investigacion Medica Internacional 10: 151–154 (1983).Google Scholar
  208. Villiaumey, J.; Avouac, B.; Chanzy, M.O. and Jean-Baptiste, G.: Piroxicam in rheumatoid arthritis —A double-blind comparative trial vs ketoprofen. Proceedings of the 15th International Congress of Rheumatology, Paris, pp.67-78 (1981).Google Scholar
  209. Wade, A.G.: A single-blind cross-over comparison of fenbufen 600mg nocte and piroxicam 20mg nocte in osteoarthritis. European Journal of Rheumatology and Inflammation 4: 357–363 (1981).PubMedGoogle Scholar
  210. Ward, J.R.; Fraback, R.; McAdam, L.P. et al.: Piroxicam in rheumatoid arthritis: A multi-center 14 week controlled double-blind study comparing aspirin and piroxicam. XIV International Congress of Rheumatology June 26–July 1, San Francisco, California, USA (1977).Google Scholar
  211. Ward, K. and Weir, D.G.: Piroxicam and upper gastrointestinal haemorrhage. Irish Medical Journal 75: 10–11 (1982).PubMedGoogle Scholar
  212. Watanabe, I.; Abe, N.; Tanaka, K.; Senda, N.; Matsukura, K.; Watanabe, C. and Hirai, S.: Anti-inflammatory and analgesic action of piroxicam, a new non-steroidal anti-inflammatory agent. Pharmacometrics 25(1): 7–18 (1983).Google Scholar
  213. Weber, J.C.P.: Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs; in Rainsford and Velo (Eds) Advances in Inflammation Research Vol. 6, pp. 1–7 (Raven Press, New York 1984).Google Scholar
  214. Weintraub, M.; Case, K.; Kroening, B. and Bosmann, H.B.: Effects of piroxicam on platelet aggregation. Clinical Pharmacology and Therapeutics 23: 134–135 (1978a).Google Scholar
  215. Weintraub, M.; Jacox, R.F.; Angevine, CD. and Atwater, E.C.: Piroxicam (CP 16171) in rheumatoid arthritis: A controlled clinical trial with novel assessment techniques. Journal of Rheumatology 4: 393–404 (1977).PubMedGoogle Scholar
  216. Weintraub, M.; Jacox, R.F.; Angevine, CD. and Atwater, E.C.: Piroxicam and rheumatoid arthritis: An 18-month open-label continuation of a double-blind study. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.53-58 (1978b).Google Scholar
  217. Widmark, P.: Safety and efficacy of piroxicam in the treatment of acute gout. European Journal of Rheumatology and Inflammation 1: 346–348 (1978).Google Scholar
  218. Widmark, P.H.: Piroxicam: Its safety and efficacy in the treatment of acute gout. American Journal of Medicine 72(2A): 63–65 (1982).Google Scholar
  219. Williamson, CM.: Clinical evaluation of piroxicam in acute musculoskeletal injuries seen in general practice. Current Medical Research and Opinion 8(a): 622–625 (1983).PubMedGoogle Scholar
  220. Willis, J.V.; Kendall, M.J.; Flinn, R.M.; Thornhill, D.P. and Welling, P.G.: The pharmacokinetics of diclofenac sodium following intravenous and oral administration. European Journal of Clinical Pharmacology 16: 405–410 (1979).PubMedGoogle Scholar
  221. Willis, J.V.; Kendall, M.J. and Jack, D.B.: A study of the effect of aspirin on the pharmacokinetics of oral and intravenous diclofenac sodium. European Journal of Clinical Pharmacology 18: 415–418 (1980).PubMedGoogle Scholar
  222. Willkens, R.F.; Ward, J.R.; Louie, J.S. and McAdam, L.P.: Double-blind study comparing piroxicam and aspirin in the treatment of rheumatoid arthritis. American Journal of Medicine 72(2A): 23–26 (1982).Google Scholar
  223. Wiseman, E.H.: Review of preclinical studies with piroxicam: Pharmacology, pharmacokinetics and toxicology. Royal Society of Medicine International Congress and Symposium Series No. 1, pp.11-23 (1978).Google Scholar
  224. Wiseman, E.H.: Piroxicam (Feldene): Theoretical design and mechanism of action. Proceedings of a symposium organized by Academy Professional Information Services, Inc., and presented at the IXth European Congress of Rheumatology, September 4, 1979, pp.2–10 (Academy Professional Information Services, New York 1980).Google Scholar
  225. Wiseman, E.H. and Boyle, J.A.: Piroxicam (Feldene). Clinics in Rheumatic Diseases 6: 585–613 (1980).Google Scholar
  226. Wiseman, E.H.; Chang, Y.-H. and Lombardino, J.G.: Piroxicam, a novel anti-inflammatory agent. Arzneimittel-Forschung 26: 1300 (1976).PubMedGoogle Scholar
  227. Wiseman, E.H. and Hobbs, D.C.: Review of pharmacokinetic studies with piroxicam. American Journal of Medicine 72(2A): 9–17 (1982).Google Scholar
  228. Wiseman, E.H. and Reinert, H.: Anti-inflammatory drugs and renal papillary necrosis. Agents and Actions 5: 322–325 (1975).PubMedGoogle Scholar
  229. Woolf, A.D.; Rogers, HJ.; Bradbrook, I.D. and Corless, D.: Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients. British Journal of Clinical Pharmacology 16: 433–437 (1983).PubMedGoogle Scholar
  230. Zizic, T.M.; Sutton, J.D. and Stevens, M.B.: Piroxicam and osteoarthritis: A controlled study. Royal Society of Medicine International Congress and Symposium Series No. 1, pp. 71–81 (1978).Google Scholar

Copyright information

© ADIS Press Limited 1984

Authors and Affiliations

  • R. N. Brogden
    • 1
  • R. C. Heel
    • 1
  • T. M. Speight
    • 1
  • G. S. Avery
    • 1
  1. 1.ADIS Drug Information ServicesBirkenhead, Auckland 10New Zealand

Personalised recommendations